权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Structure, Function and Mechanistic Analysis of LAG3

LAG3的结构、功能及机理分析

基本信息

批准号：
10542350
负责人：
Roy A Mariuzza
金额：
$ 71.2万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-01-08 至 2024-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10542350
关键词：
Address Affinity Agonist Amino Acids Autoimmune Diseases Autoimmunity Binding Biological Process Biophysics Blocking Antibodies CD3 Antigens CD4 Positive T Lymphocytes CD8-Positive T-Lymphocytes CTLA4 gene Cell physiology Cells Chronic Clinic Clinical Trials Clustered Regularly Interspaced Short Palindromic Repeats Complex Data Development Disease Dissection Epitopes Generations Goals Human Immune Immunity Immunotherapeutic agent Immunotherapy Inflammatory Ligands MHC Class II Genes Maps Mediating Modeling Monoclonal Antibodies Mus Mutagenesis Mutant Strains Mice Play Positioning Attribute Reagent Research Role Site Structure T-Lymphocyte Testing Therapeutic Therapeutic Monoclonal Antibodies Tissues Treatment Efficacy Viral Cancer Virus Diseases Work antagonist anti-PD-1 cancer therapy comparative effector T cell exhaust in vitro Assay insight mutant novel overexpression prevent programmed cell death protein 1 receptor reconstitution response screening panel targeted treatment tool tumor

项目摘要

LAG3 (CD233) is an inhibitory receptor that plays a critical role in controlling T cell tolerance, preventing autoimmunity and limiting immune-mediated tissue damage. It is highly upregulated on exhausted T cells in tumors and in chronic viral infections, limiting the development of sterilizing immunity. Consequently, LAG3 is now a major immunotherapeutic target for the treatment of cancer and other diseases, with multiple clinical trials ongoing. Despite extensive analysis of LAG3 for over 30 years and multiple LAG3 targeting therapeutics in the clinic, very little is known about the mechanism of action of LAG3 and thus how to develop optimal LAG3- targeting therapeutics, especially agonists. While it is assumed that the primary and perhaps only functionally relevant ligand for LAG3 is MHC class II, there are several observations including our recent preliminary studies that suggest that there are additional biophysical requirements for LAG3 to function. AIM 1: Define and compare LAG3 interaction with its ligands. We will address 3 questions: (A) Which domains and residues mediate LAG3 interaction with its ligands? (B) Can the association of LAG3 with its ligands be disrupted by different anti-LAG3 Abs? (C) What LAG3 residues mediate ligand interaction? AIM 2: Determine crystal structures of LAG3 and of LAG3:Ab and LAG3:MHC class II complexes. We will address the structural basis for the biological function of LAG3 by asking 3 questions: (A) What unique structural features of LAG3 distinguish it from CD4? (B) What is the structure of LAG3:Ab complexes? (C) What is the structure of LAG3:MHC class II complexes? AIM 3: Determine the functional impact of LAG3 interaction with its ligands. We will address 3 questions: (A) Is LAG3 association with its various ligands required for its function? (B) Does LAG3 interaction with its various ligands have a differential impact on its function in tumor models? (C) Is blocking the association of LAG3 with its different ligands have differential therapeutic benefit? This project will have a significant impact on our understanding of the mechanism of action of LAG3, as well as provide further insight into the generation of enhanced therapeutic reagents that block or enhance LAG3 function. Given that we have determined the function of LAG3 on regulatory and effector T cell function, have been studying LAG3 function of ~19 years, have available to us a variety of unique tools to probe its function and have assembled a strong and technically diverse collaborative team, we are in the best position to conduct this research.